This is an observational study for patients who are receiving IV Krystexxa for gout refractory to other treatment. This drug is not supplied by the study.

• Patients who have failed to normalize SUA and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose, or for whom these drugs are contraindicated.
• Patients who have made the decision, along with their treating physician, to begin treatment with KRYSTEXXA.

Contact Candace LeBlanc at 508-556-5431 or Marcy Kirkpatrick at 508-556-5429 for more information.